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Background: Rho kinase plays an important role in vascular smooth muscle cell (VSMC) contraction and other cellular
functions, such as proliferation, migration, and apoptosis. Recent studies have demonstrated that long-term inhibition of
Rho kinase suppresses coronary artery spasm and vascular lesion formation after arterial injury. In the cardiovascular
surgery field, intimal thickening in vein grafts is the major cause of late graft failure, for which no effective treatment has
yet been developed. In this study, we examined whether long-term inhibition of Rho kinase suppresses intimal thickening
in autologous vein grafts in rabbits.
Methods:Male rabbits were randomly divided into two groups and received normal chow (control group) or a special chow
containing 0.09% fasudil (fasudil group). After oral administration, fasudil is metabolized to a specific Rho kinase
inhibitor, hydroxyfasudil. Each group underwent reversed autologous vein graft surgery with the internal jugular vein
into the left common carotid artery. At 1, 2, and 4weeks after the operation, we examined the extent of intimal thickening
of the graft and VSMC proliferation and apoptosis.
Results:The intimal thickening was significantly suppressed in the fasudil group compared with the control group at 2 and
4 weeks after the operation. In the fasudil group, VSMC proliferation was suppressed at 1 and 2 weeks after the
operation, whereas VSMC apoptosis was enhanced at 2 weeks after the procedure.
Conclusions: These results indicate that Rho kinase is substantially involved in the pathogenesis of intimal thickening of
vein grafts and that it is an important therapeutic target for the prevention of graft failure. ( J Vasc Surg 2006;43:
1249-56.)For vascular occlusive diseases, an autologous vein graft
is the most suitable conduit for arterial reconstruction;
however, late graft failure remains a serious problem that
limits the long-term efficacy of the procedure.1 Among the
possible mechanisms involved, intimal thickening seems to
be the major cause of the disorder.2,3 It is characterized by
enhanced migration and proliferation of vascular smooth
muscle cells (VSMCs) from the media into the intima
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doi:10.1016/j.jvs.2006.02.035after transplantation into the arterial circulation.4,5 Sev-
eral experimental and clinical studies have attempted to
reduce the intimal thickening of the graft. However, no
effective pharmacologic therapy has yet been developed
for human use.4,5
Rho kinase, a target protein of the small guanosine
triphosphatase Rho, regulates vascular tone through a
Ca2 sensitization mechanism and plays an important role
in VSMC contraction.6,7 Phosphorylation of the myosin
light chain (MLC) is one of the essential steps for VSMC
contraction, the level of which is regulated by MLC kinase
and MLC phosphatase.6,7 Recent studies have demon-
strated that Rho regulates MLC phosphorylation through
Rho kinase and MLC phosphatase.8,9 The Rho/Rho kinase
pathway also plays an important role in other cellular func-
tions, such as actin cytoskeleton organization, adhesion and
migration, cytokinesis, proliferation, and apoptosis. 10-13 We
have recently demonstrated that long-term inhibition of
Rho kinase by either a Rho kinase inhibitor or in vivo gene
transfer of dominant-negative Rho kinase suppresses coro-
nary artery spasm and vascular lesion formation in various
animal models.14-19 Thus, this study was designed to ex-
amine whether long-term inhibition of Rho kinase sup-
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to elucidate the mechanisms involved.
METHODS
This study was reviewed by the Committee on Ethics
on Animal Experiments of Kyushu University and was
performed under the Guidelines for Animal Experiments of
Kyushu University and the law (No. 105) and the notifica-
tion (No. 6) of the Japanese Government.
Autologous vein graft surgery. A total of 70 male
Japanese White rabbits weighing 2.5 to 3.0 kg were ran-
domly divided into 2 groups: (1) a control group that
received normal chow and (2) a fasudil group that received
a special chow containing 0.09% fasudil 30 mg/kg. In a
previous study, long-term administration of fasudil (30
mg/kg) was effective for suppressing arterial neointimal
formation in the porcine model20 and for suppressing
cardiovascular hypertrophy in the rat model.21 Therefore,
we used this dose in the current study. Fasudil is metabo-
lized to a selective inhibitor for Rho kinase,21 hydroxyfa-
sudil, after oral administration.16,17 The fasudil treatment
was started 3 days before the operation and was continued
for 4 weeks, until the end of the experiment. Anesthesia was
induced with xylazine (10 mg/kg subcutaneously) and
ketamine hydrochloride (25 mg/kg intramuscularly) and
was maintained with pentobarbital sodium (30 mg/kg
intravenously). Under sterile conditions, the left internal
jugular vein and the left common carotid artery were ex-
posed, and the branches of the jugular vein were ligated.22
The vein was then excised and was kept moistened in
heparinized (5 U/mL) saline solution. Heparin (1000 U
per body) was administered intravenously. The left carotid
artery was clamped at the proximal and distal ends. A
proximal longitudinal arteriotomy was made, and the vein
was reversed and anastomosed to the artery in an end-to-
side manner.22 Distal anastomosis was performed in a sim-
ilar manner, and then the carotid artery was divided. The
wound was closed in layers.
Blood sample analysis. Blood was obtained from the
middle ear artery at the time of operation and at 1, 2, and 4
weeks after the operation. In addition, plasma concentra-
tions of hydroxyfasudil were assayed by high-performance
liquid chromatography.
Blood pressure measurement. At the operation and
4 weeks after the operation, blood pressure was measured
through a cannula placed in the middle ear artery by using
a pressure transducer connected to a polygraph monitoring
system. All measurements were made 5 minutes after the
induction of anesthesia, when all hemodynamic variables
were stabilized.
Harvest of implanted vein grafts. At 1, 2, and 4
weeks after the operation, the animals in both groups were
killed with a lethal dose of pentobarbital (n  7 in each
group). The vein grafts were exposed and removed and
were perfusion-fixed in situ at 100 cmH2O for 15 minutes.
The perfused vein graft, including the anastomosis, was
immersed in neutralized 10% formaldehyde overnight at
room temperature.MLC phosphorylation. To examine Rho kinase ac-
tivity, we measured the extent of phosphorylated MLC in
vein grafts at 4 weeks after the operation with serotonin at
a concentration of 106 mol/L. The extent of MLC phos-
phorylation in the grafts was determined by using the
urea/glycerol gel method, followed by immunoblot detec-
tion with a specific mouse monoclonal anti-MLC antibody,
as previously described.16,17,23 Both unphosphorylated
and phosphorylated forms of the 20-kd MLC were de-
tected by the specific antibody (200 dilution) and a
secondary antibody (1000 dilution). The region contain-
ing MLC was visualized with an ECL-Plus Western blot-
ting system (Amersham, Buckinghamshire, UK). After the
image of the radiograph film was obtained with a charge-
coupled device camera (Affo, Tokyo, Japan), the density of
unphosphorylated and phosphorylated MLCs was deter-
mined by an NIH Image analyzer (version 1.61). The
percentage of the phosphorylated form in the total MLC
was determined to express the extent of MLC phosphory-
lation.
Organ chamber experiment. Four weeks after the
operation, VSMC contractile responses were examined in
vitro. The vein grafts from the control and the fasudil group
(n  4 each) were cut into rings 3 to 4 mm in length.
Because we have repeatedly confirmed that the endothe-
lium has no inhibitory effect on the contractions of normal
veins or vein grafts,24 we used rings with endothelium
throughout the experiment. The rings were suspended by
hooks in an organ bath that contained oxygenated Krebs
solution of the following composition (mmol/L): NaCl
121.3, KCl 4.7, NaHCO3 24.7, KH2PO4 1.2,MgSO4 1.2,
CaCl2 2.5, and D-glucose 5.77, bubbled with 95% oxygen
and 5% carbon dioxide and maintained at 37 °C.19 The
hooks were connected to a force transducer (Nihon Kohden,
Tokyo, Japan), and the data were stored in a computer using
MacLab. After a 40-minute equilibration period, the rings
were stimulated with 60 mmol/L KCl every 30 minutes, and
the resting tension was increased in a stepwise manner to
achieve a maximal force development. The rings were then
exposed to increasing concentrations of KCl (5-100 mmol/
L). After washout, the vasoconstrictor responses to increasing
concentrations of serotonin (109 to 105 mol/L) were
examined in the presence and absence of hydroxyfasudil
(105 mol/L). The responses were expressed as a percent-
age of the contractions to 60 mmol/L KCl that caused
maximal contractions.25
Intimal thickening. The sections were stained with
hematoxylin and eosin and Elastica–van Gieson stainings.
Four sections were obtained from each vein graft. The
extent of maximal intimal thickness was measured by
Macscope (Mitani Co, Fukai, Japan) at eight random
points in each section.22 The quantitative analysis was
performed in four independent sections. The average of the
eight points was considered to represent the intimal thick-
ening of the section, and the average of the four sections
was considered to represent that of the graft. The intimal
area was also calculated in the same manner. For the exam-
ination of constructive remodeling, we measured the
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the operation. All analyses were performed in a blinded
manner.
Immunohistochemical stainings. Proliferating cell nu-
clear antigen (PCNA) staining was performed as follows.
Briefly, formalin-fixed, paraffin-embedded tissue sections
were cut into 3-m sections, mounted on silanated slides,
deparaffinized in xylene, and rehydrated in a graded series of
ethanol. Endogenous peroxidase activitywas blockedbyusing
methanol containing 0.3%H2O2. To avoid nonspecific bind-
ing, the slides were preincubated with 3% skim milk for 30
minutes. Sections were incubated with primary monoclonal
antibody against PCNA (DAKO, Kyoto, Japan) and refriger-
ated overnight at 4 °C. The primary antibody was visualized
with a streptavidin-biotin-peroxidase kit (Nichirei, Tokyo,
Japan) with diaminobenzidine tetrahydrochloride as a chro-
mogen. These sections were then lightly counterstained by
hematoxylin.
For detection of apoptotic cells, we performed terminal
transferase-mediated deoxyuride-5=-triphosphate nick-end
labeling (TUNEL) staining (Takara In Situ Apoptosis De-
tection Kit; Takara Co, Ohtsu, Japan) in accordance with
the manufacturer’s protocol. The counterstaining was per-
formed with methyl green. VSMCs and macrophages were
detected by monoclonal mouse anti-human -smooth
muscle actin (DAKO) and monoclonal mouse anti-rabbit
macrophage 11 (DAKO), respectively.
The number of PCNA- and TUNEL-positive VSMCs
was counted in the intima at a magnification of 400 in a
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Fig 1. Suppression of myosin light chain (MLC) phosphorylation
(MLC-P) by fasudil. The extent of MLC phosphorylation was
significantly inhibited in the fasudil group compared with the
control group. Results are expressed as the mean  SEM.blinded manner, and the ratio of the number of PCNA-and TUNEL-positive cells to that of total VSMCs was
obtained. The quantitative analysis was performed in eight
independent sections. The average of the eight values was
considered to be the ratio of positive cells in one section,
and the average of the four values was considered to repre-
sent that of one vein graft.
Statistical analysis. All results are expressed as the
mean  SEM. The data were analyzed by using one-way
analysis of variance followed by the Scheffé post hoc test. A
value of P  .05 was considered to be statistically signifi-
cant.
RESULTS
Animals and graft patency. Eight rabbits were used
for the examination of MLC phosphorylation. Sixteen
rabbits were used for the organ chamber experiment.
Forty-two rabbits were used for the analysis of intimal
thickening and immunohistochemical stainings. Four
rabbits died during the induction of intravenous anes-
thesia (pentobarbital sodium). All vein grafts were patent
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Fig 2. Suppression of vascular smooth muscle cell (VSMC) hy-
percontraction of vein grafts by fasudil. In the control group,
serotonin caused VSMC hypercontractions as compared with the
normal jugular vein, and these hypercontractions were significantly
inhibited by acute administration of fasudil to the level seen in the
fasudil group. Results are expressed as the mean  SEM.
Table. Intimal thickening (m) of vein grafts
Time (wk)
Control group
(n  7)
Fasudil group
(n  7)
1 26.19  0.99 22.63  0.46
(20.41-31.22) (18.93-27.50)
2 54.58  3.27 34.86  2.96*
(27.05-82.50) (21.63-62.79)
4 74.37  2.99 47.64  2.84*
(48.78-111.95) (23.63-83.48)
Data are mean  SEM (range).
*P  .01 vs control group.until the harvest.
he m
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difference in body weight between the groups (data not
shown). Systolic blood pressure was also similar between
the control and the fasudil groups (92  5 mm Hg and
89  2 mm Hg at the operation and 87  2 mm Hg and
87  1 mmHg at 4 weeks after the operation, respectively;
n  7 in each group). The plasma concentrations of hy-
droxyfasudil were 0 ng/mL in the control group and
251  58 ng/mL, 197  70 ng/mL, and 270  66
ng/mL in the fasudil group at 1, 2, and 4 weeks after the
operation, respectively (n  4 each). These concentrations
of hydroxyfasudil were within the specific therapeutic range
Fig 3. Suppression of intimal thickening of the vein g
portion of an autologous vein graft from the control and
Gieson stain; original magnification, 200). Intimal thi
compared with the control group. (B) Quantitative a
thickening was significantly suppressed in the fasudil gro
analysis of the intimal area of vein grafts. The intimal are
weeks (W) after the operation. Results are expressed as tof the Rho kinase inhibitor.16,17Suppression of MLC phosphorylation by fasudil.
The extent of MLC phosphorylation (the phosphorylated
form in the percentage of total MLC) at 4 weeks after the
operation was significantly suppressed in the fasudil group
compared with the control group (Fig 1).
Suppression of VSMC hypercontraction by fasudil.
There was no significant difference in the KCl-induced maxi-
mal contraction between the control (3.47 0.42 g) and the
fasudil (3.87  0.41 g) groups. Serotonin caused hypercon-
tractions of vein grafts in the control group, which were
markedly inhibited by acute administration of hydroxyfasudil
to the level seen in the fasudil group (Fig 2). In contrast,
y fasudil. (A) Representative photographs of the mid
fasudil groups 4 weeks after the operation (Elastica–van
ng (as shown by I) was suppressed in the fasudil group
s of the intimal thickness of vein grafts. The intimal
2 and 4 weeks (W) after the operation. (C) Quantitative
significantly suppressed in the fasudil group at 2 and 4
ean  SEM.raft b
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control group, intimal thickening, as evaluated by either max-
imal intimal thickness or intimal area, progressively developed
andwas significantly suppressed in the fasudil group at 2 and 4
weeks after the operation (Table; Fig 3). Four weeks after the
operation, the inside diameter of the internal elastic lamina
was 4779.8 339.5 m in the control group and 3892.9
314.0 m in the fasudil group (not significantly different).
Suppression of VSMC proliferation by fasudil. The
number of PCNA-positive cells, a marker of VSMC prolif-
eration,22,26 was significantly reduced in the fasudil group
compared with the control group at 1 and 2 weeks after the
operation (Fig 4).
Enhancement of VSMC apoptosis by fasudil. VSMC
apoptosis was evaluated by TUNEL staining.26,27 Two weeks
after the operation, the number of TUNEL-positive VSMCs
was significantly higher in the fasudil group compared with
Fig 4. Vascular smooth muscle cell (VSMC) prolifera
ating cell nuclear antigen (PCNA) staining of the mid
fasudil groups 2 weeks after the operation. Arro
fication,400). (B) Quantitative analysis of the freque
suppressed in the fasudil group at 1 and 2 weeks (W) afthe control group (Fig 5).No influence of fasudil on macrophage infiltration.
The number of macrophages detected by anti-rabbit mac-
rophage 11 staining (number per 400 visual field) was
low throughout the experimental period in the control and
the fasudil groups: 0.7  0.2 and 0.9  0.3 at 1 week,
0.9  0.2 and 0.7  0.2 at 2 weeks, and 0.4  0.1 and
0.5  0.1 at 4 weeks after the operation, respectively (no
statistical differences were found).
DISCUSSION
The novel findings of this study were that (1) long-term
inhibition of Rho kinase by fasudil suppressed the develop-
ment of intimal thickening of vein grafts and (2) suppres-
sion of VSMC serotonin-induced hypercontraction and
proliferation and enhancement of VSMC apoptosis were
involved in the inhibitory effects of fasudil. To the best of
in vein grafts. (A) Microscopic findings with prolifer-
tion of an autologous vein graft from the control and
ds show PCNA-positive VSMCs (original magni-
f PCNA-positive cells. The frequency was significantly
e operation. Results are expressed as the mean SEM.tion
por
whea
ncy oour knowledge, this is the first report that demonstrates the
JOURNAL OF VASCULAR SURGERY
June 20061254 Furuyama et alusefulness of Rho kinase inhibitors for the prevention of
vein graft disease.
Hydroxyfasudil, which is a metabolite of fasudil after
oral administration, is a specific inhibitor of Rho kinase. 16,17
Fasudil is used for the treatment of cerebral vasospasm after
subarachnoid hemorrhage. In this study, fasudil did not
influence systemic blood pressure, body weight, or survival
until 4 weeks after the operation. In humans, oral admin-
istration of fasudil is well tolerated, without any serious
adverse reactions.18,28
Rho kinase enhances the Ca2 sensitivity of VSMCs
through inhibition of MLC phosphatase, which results in
enhanced MLC phosphorylation.6,7 In this study, MLC
phosphorylation was significantly inhibited in the fasudil
group, thus demonstrating an inhibition of Rho kinase by
Fig 5. Terminal transferase-mediated deoxyuride-5=-t
smooth muscle cells (VSMCs) in thickened intima. (A) M
of autogenous vein grafts from the control and fasu
TUNEL-positive cells (original magnification, 400). (
cells. The frequency was significantly higher in the fasud
the operation. Results are expressed as mean  SEM.long-term oral treatment with fasudil. We have recentlydemonstrated that Rho kinase is substantially involved in
the pathogenesis of hypercontraction of arteriosclerotic
arteries and of coronary artery spasm both in animals and
humans.14-19,28 In this study, serotonin-induced contrac-
tions of vein grafts were enhanced, which is consistent with
our previous report25; these were markedly suppressed in
the fasudil group.
VSMC serotonin-induced hypercontraction and prolif-
eration seem to be closely coupled in terms of an involve-
ment of Rho kinase, because we have recently observed that
long-term inhibition of Rho kinase, either by in vivo gene
transfer of dominant-negative Rho kinase or by long-term
treatment with fasudil, causes a regression of both vascular
vasospastic activity and arteriosclerosis.14-19 A similar result
has also been reported in a clinical study with patients with
sphate nick-end labeling (TUNEL)-positive vascular
copic findings with TUNEL staining of the mid portion
oups 2 weeks after the operation. Arrowheads show
antitative analysis of the frequency of TUNEL-positive
up compared with the control group 2 weeks (W) afterripho
icros
dil gr
B) Qu
il grovasospastic angina, in which coronary vasospastic activity
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coupled.29
Intimal thickening of autologous vein grafts is the major
cause of late graft failure.2,3 The intimal thickening is charac-
terized by enhanced proliferation and migration of VSMCs
from the media into the intima.4,5 We have previously re-
ported that intimal thickening was observed as early as 1 week
after the operation and thereafter progressively increased, 30
whereas another study showed thatVSMCproliferation in the
intima peaked from 1 to 2 weeks after the operation.31,32 We
also reported that intimal thickening in the vein graft had
progressed remarkably by 4 weeks and that it had reached a
peak at this time.24,30 Our present results confirm the time
course of intimal thickening in the rabbit model22 and are also
consistent with the previous report on VSMC proliferation as
evaluated by PCNA staining.26,27 It is important to note that
in this study, the long-term inhibition of Rho kinase with
fasudil suppressed the development of intimal thickening as
well as VSMCproliferation, thus indicating an involvement of
Rho kinase–mediated VSMC proliferation. Indeed, it has
been reported that long-term inhibition of Rho kinase by
either a Rho kinase inhibitor33,34 or in vivo gene transfer of
dominant-negative Rho kinase14 suppresses intimal thick-
ening after balloon injury.
VSMC migration from the media into the intima also
plays an important role in intimal thickening in arterioscle-
rosis.4,5 MLC phosphorylation, focal adhesion complex,
and actin stress fiber formation, all of which are regulated
by Rho kinase, may be involved in VSMC migration.10-13
Although we did not specifically address this point in this
study, it is possible that VSMC migration was also inhib-
ited, because Rho kinase inhibitors suppress VSMC migra-
tion in vivo and in vitro.35-37
Another possible mechanism for the inhibition of intimal
thickening by fasudil is the enhancement of VSMC apoptosis.
It has been demonstrated in the experimental animal model
that the regression of intimal thickening is associated with
enhanced VSMC apoptosis.38,39 We have recently demon-
strated in a porcine model of in-stent restenosis that blockade
of Rho kinase with fasudil enhances VSMC apoptosis, thus
resulting in the suppression of the restenosis.20 Thus, it is
highly possible that apoptosis also plays a role in the suppres-
sion of intimal thickening of vein grafts.
We previously showed that long-term inhibition of
Rho kinase by hydroxyfasudil or gene transfer of domi-
nant-negative Rho kinase induced a marked regression of
the constructive remodeling of porcine coronary artery
in the experimental model.11,15,17,40 However, in the
vein graft, the external elastic lamina was unclear, and
thus the external elastic lamina length could not be
precisely measured. We examined the inside diameter of
the internal elastic lamina for the surrogate measure, but
there was no significant difference between the groups.
This suggested that constructive remodeling may not
play an important role in an autologous vein graft model.
In this study with an autologous vein graft model,
macrophage infiltration was not substantially involved in
the pathogenesis of intimal thickening. This is a findingsimilar to our previous study.31 This suggested that macro-
phages may not play an important role to accelerate neoin-
timal formation in normolipidemia.
In summary, we were able to demonstrate that the
long-term inhibition of Rho kinase suppresses intimal
thickening of autologous vein grafts in rabbits, for which
inhibition of VSMC proliferation and enhancement of
VSMC apoptosis may be involved. Thus, Rho kinase
inhibitors may be useful for the prevention of vein graft
disease.
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